D-二聚体水平与放化疗肺癌患者预后的关系:系统评价与Meta分析
Relationship between D-Dimer Level and Prognosis in Patients with Lung Cancer after Chemoradiotherapy: A Systematic Review and Meta-Analysis
DOI: 10.12677/ACM.2023.133683, PDF,   
作者: 雷 春, 吴刚杰:暨南大学第一临床医学院,广东 广州;朱晓峰*:暨南大学附属第一医院中医科,广东 广州
关键词: D-二聚体肺癌放化疗预后D-Dimer Lung Cancer Chemoradiotherapy Prognosis
摘要: 目的:系统评价放化疗前肺癌患者的血浆D-二聚体水平与其生存预后之间的关系。方法:通过计算机检索国内外相关数据库,收集所有符合纳入标准的文献,检索时限从建库起至2022年11月。由两名研究人员分别对检索出的文献按纳入与排除标准筛选文献、提取资料。采用Revman 5.4软件进行Meta分析。结果:最终纳入12篇文献,包括1602名患者进行分析。Meta分析结果显示D-二聚体水平高的放化疗肺癌患者相比于D-二聚体水平正常的放化疗肺癌患者有较差的PFS (HR: 1.70, 95% CI: 1.48, 1.96; P < 0.00001)和OS (HR: 1.82, 95% CI: 1.99, 2.81; P < 0.00001),差异具有统计学意义。结论:高血浆D-二聚体水平可能是放化疗的肺癌患者评估预后的预测因子。
文章引用:雷春, 吴刚杰, 朱晓峰. D-二聚体水平与放化疗肺癌患者预后的关系:系统评价与Meta分析[J]. 临床医学进展, 2023, 13(3): 4775-4784. https://doi.org/10.12677/ACM.2023.133683

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Krist, A.H., Davidson, K.W., Mangione, C.M., et al. (2021) Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 325, 962-970. [Google Scholar] [CrossRef] [PubMed]
[3] 李磊, 张卫东. 小细胞肺癌的化疗、免疫治疗及靶向治疗研究进展[J]. 山东医药, 2022, 62(29): 95-98.
[4] Liu, L., Zhang, X., Yan, B., et al. (2014) Elevated Plasma D-Dimer Levels Correlate with Long Term Survival of Gastric Cancer Patients. PLOS ONE, 9, e90547. [Google Scholar] [CrossRef] [PubMed]
[5] Diao, D., Zhu, K., Wang, Z., et al. (2013) Prognostic Value of the D-Dimer Test in Oesophageal Cancer during the Perioperative Period. Journal of Surgical Oncology, 108, 34-41. [Google Scholar] [CrossRef] [PubMed]
[6] De Cicco, M. (2004) The Prothrombotic State in Cancer: Pathogenic Mech-anisms. Critical Reviews in Oncology/Hematology, 50, 187-196. [Google Scholar] [CrossRef] [PubMed]
[7] Nakamura, K., Nakayama, K., Ishikawa, M., et al. (2016) High Pre-Treatment Plasma D-Dimer Level as a Potential Prognostic Biomarker for Cervical Carcinoma. Anticancer Re-search, 36, 2933-2938.
[8] Ferroni, P., Roselli, M., Portarena, I., et al. (2014) Plasma Plasminogen Activator Inhibi-tor-1 (PAI-1) Levels in Breast Cancer—Relationship with Clinical Outcome. Anticancer Research, 34, 1153-1161.
[9] Stender, M.T., Larsen, T.B., Sørensen, H.T. and Thorlacius-Ussing, O. (2012) Preoperative Plasma D-Dimer Predicts 1-Year Survival in Colorectal Cancer Patients with Absence of Venous Thromboembolism (VTE): A Prospective Clinical Cohort Study. Journal of Thrombosis and Haemostasis, 10, 2027-2031. [Google Scholar] [CrossRef] [PubMed]
[10] 崔洪霞, 左学荣, 陈艳, 马丽霞. 非小细胞肺癌患者血浆D-二聚体水平及其临床意义[J]. 临床医药文献电子杂志, 2019, 6(94): 138-139.
[11] Tas, F., Kilic, L., Serilmez, M., et al. (2013) Clinical and Prognostic Significance of Coagulation Assays in Lung Cancer. Respiratory Medicine, 107, 451-457. [Google Scholar] [CrossRef] [PubMed]
[12] Guo, J., Gao, Y., Gong, Z., et al. (2021) Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treat-ment of Non-Small-Cell Lung Cancer (NSCLC) Patients. BioMed Research International, 2021, Article ID: 9623571. [Google Scholar] [CrossRef] [PubMed]
[13] Stang, A. (2010) Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. European Journal of Epidemiology, 25, 603-605. [Google Scholar] [CrossRef] [PubMed]
[14] Zhang, C., Jia, Y., Jia, Y., et al. (2018) Prognostic and Predictive Value of Plasma D-Dimer Levels in Patients with Small-Cell Lung Cancer. International Journal of Clinical Oncology, 23, 1070-1075. [Google Scholar] [CrossRef] [PubMed]
[15] Ge, L.P., Li, J., Bao, Q.L., et al. (2015) Prognostic and Predictive Value of Plasma D-Dimer in Advanced Non-Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy. Clinical and Translational Oncology, 17, 57-64. [Google Scholar] [CrossRef] [PubMed]
[16] Zhu, L.R., Li, J., Chen, P., et al. (2016) Clinical Significance of Plasma Fibrinogen and D-Dimer in Predicting the Chemotherapy Efficacy and Prognosis for Small Cell Lung Cancer Pa-tients. Clinical and Translational Oncology, 18, 178-188. [Google Scholar] [CrossRef] [PubMed]
[17] Abbas, M., Kassim, S.A., Wang, Z.C., et al. (2020) Clinical Evaluation of Plasma Coagulation Parameters in Patients with Ad-vanced-Stage Non-Small Cell Lung Cancer Treated with Palliative Chemotherapy in China. International Journal of Clinical Practice, 74, e13619. [Google Scholar] [CrossRef] [PubMed]
[18] Fan, S., Zhao, G. and An, G. (2019) High Pretreatment Plasma D-Dimer Levels Are Associated with Shorter Overall Survival in Patients with Small Cell Lung Cancer. Journal of International Medical Research, 47, 215-224. [Google Scholar] [CrossRef] [PubMed]
[19] Xu, W., Yang, M., Zhao, C., et al. (2021) Massive Spondylecto-my for Metastatic Spinal Cord Compression from Non-Small-Cell Lung Cancer with Local Failure after Radiotherapy. Global Spine Journal, 11, 549-555. [Google Scholar] [CrossRef] [PubMed]
[20] Jiang, X., Mei, X., Wu, H. and Chen, X. (2017) D-Dimer Level Is Related to the Prognosis of Patients with Small Cell Lung Cancer. Annals of Translational Medicine, 5, 394. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, Y., Yu, H., Wu, C., et al. (2016) Prognostic Value of Plasma D-Dimer Levels in Patients with Small-Cell Lung Cancer. Biomedicine & Pharmacotherapy, 81, 210-217. [Google Scholar] [CrossRef] [PubMed]
[22] 田晴文. 广泛期小细胞肺癌临床病理特征与PFS的相关性分析[D]: [硕士学位论文]. 郑州: 郑州大学, 2019.
[23] 郑秋青, 毛伟敏, 谢发君. 血浆D-二聚体水平与晚期非小细胞肺癌患者临床预后相关性研究[J]. 分子诊断与治疗杂志, 2014(6): 384-387.
[24] Altiay, G., Ciftci, A., Demir, M., et al. (2007) High Plasma D-Dimer Level Is Associated with Decreased Survival in Patients with Lung Cancer. Clinical Oncology (Royal College of Radiologists), 19, 494-498. [Google Scholar] [CrossRef] [PubMed]
[25] Wolny-Rokicka, E.I., Wydmański, J., Tukiendorf, A., Mróz, P. and Zembroń-Łacny, A. (2018) Appraisal of Basic Hemostatic Markers in Lung Cancer Patients during Follow-Up Care after Radiotherapy Treatment. Medical Science Monitor, 24, 8577-8582. [Google Scholar] [CrossRef
[26] Blom, J.W., Osanto, S. and Rosendaal, F.R. (2004) The Risk of a Venous Thrombotic Event in Lung Cancer Patients: Higher Risk for Adenocarcinoma than Squamous Cell Carcinoma. Journal of Thrombosis and Haemostasis, 2, 1760-1765. [Google Scholar] [CrossRef] [PubMed]
[27] Jiang, D. and Lee, A.I. (2019) Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treatment Research, 179, 87-101. [Google Scholar] [CrossRef] [PubMed]
[28] Kvolik, S., Jukic, M., Matijevic, M., Marjanovic, K. and Gla-vas-Obrovac, L. (2010) An Overview of Coagulation Disorders in Cancer Patients. Surgical Oncology, 19, e33-e46. [Google Scholar] [CrossRef] [PubMed]
[29] Qdaisat, A., Wu, C.C. and Yeung, S.J. (2019) Normal D-Dimer Levels in Cancer Patients with Radiologic Evidence of Pulmonary Embolism. Journal of Thrombosis and Thrombolysis, 48, 174-179. [Google Scholar] [CrossRef] [PubMed]
[30] 王鑫, 张涛, 马学真, 孙宏权, 马光红. 血栓弹力图与常用凝血指标相关性及联合检测对晚期肺癌高凝状态评估价值[J]. 中华肿瘤防治杂志, 2020, 27(6): 464-469.
[31] Deng, H.Y., Ma, X.S., Zhou, J., et al. (2021) High Pretreatment D-Dimer Level Is an Independent Unfavorable Prognostic Factor of Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 100, e25447. [Google Scholar] [CrossRef